Journey Medical Corporation · NASDAQ:DERM
Journey Medical — Investor Presentation (October 2026)
25 slides from Journey Medical's investor presentation, October 2026
Slide 1: Investor Presentation October 2026
INVESTOR PRESENTATION October 2026 Claude Maraoui Co-Founder, President and CEO Joseph Benesch PRESENTED BY: Chief Financial Officer Ramsey Alloush Chief Operating Officer 1 | © 2026 Journey Medical Corporation. All rights reserved.
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS FORWARD-LOOKING STATEMENTS This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press r
Slide 3: NASDAQ: DERM Market Data
NASDAQ: DERM Market Cap: $190MM* Shares Outstanding: 28.2MM* Average Volume: 185K* 3 | © 2026 Journey Medical Corporation. All rights reserved. *Market data as of 10/1/2026
Slide 4: Investment Highlights
INVESTMENT HIGHLIGHTS ✓ Commercial-stage pharmaceutical company focused on proprietary & patented products serving prescription dermatology markets with a total market size of ~$5.8 billion1 (acne, rosacea, hyperhidrosis) ✓ Dermatology product portfolio with 2025 net product revenues of $61 million
Slide 5: Senior Management with Significant Dermatology Experience
SENIOR MANAGEMENT WITH SIGNIFICANT DERMATOLOGY EXPERIENCE Claude Maraoui Joseph Benesch Robert Nevin Ramsey Alloush Srinivas Andrew Zwible Brian Prout Jessica Yeaman Founder, President Chief Financial Officer Chief Commercial Officer Chief Operating Officer Sidgiddi, M.D. Vice President, Executive D
Slide 6: Our Leaders Have Launched Many Successful Dermatology Brands
OUR LEADERS HAVE LAUNCHED MANY SUCCESSFUL DERMATOLOGY BRANDS Experience growing & managing marquee medical dermatology brands that generated over $2B in sales 1: A majority of our management team and sales force were part of the commercial organization at Medicis (which was sold to Bausch Health Com
Slide 7: Unique and Experienced Dermatology Sales Force
OUR COMMERCIAL ORGANIZATION IS HIGHLIGHTED BY A UNIQUE AND EXPERIENCED DERMATOLOGY SALES FORCE HIGHLIGHTS & SALES EXPERIENCE 7 yrs. 258 yrs. 92 8 64 Avg. Dermatology Combined Experience Regional Sales Sales Rookies President’s Club Sales Experience in Dermatology Awards of the Year Trophies 40 DERMA
Slide 8: Five Core Dermatology Brands; EMROSI Is the Key Growth Driver
FIVE CORE DERMATOLOGY BRANDS; EMROSI IS THE KEY GROWTH DRIVER ® • Treatment of inflammatory lesions of non-nodular • Glycopyrronium 2.4% cloth for topical treatment of moderate to severe acne vulgaris primary axillary hyperhidrosis • The first and only FDA-approved topical formulation of • 60% presc
Slide 9: U.S. Commercial Launch April 2025
U.S. Commercial Launch April 2025 Leveraging Journey Medical’s Dermatology-Focused Commercial Platform & Business Development Strategy 9 | © 2026 Journey Medical Corporation. All rights reserved.
Slide 10: EMROSI: Commercial Highlights
EMROSI : COMMERCIAL HIGHLIGHTS ® • Emrosi received FDA approval in November 2024; On time, first-cycle review • Superior to both placebo and Oracea® (doxycycline, 40 mg) • Emrosi has potential to become the standard of care • 17 million Americans suffer from rosacea1 • Established dermatology-focuse
Slide 11: EMROSI: Potential Best-in-Class Treatment for Rosacea
EMROSI : POTENTIAL BEST-IN-CLASS TREATMENT FOR ROSACEA ® PRODUCT PROFILE INDICATION1 Treatment of inflammatory lesions (papules and pustules) of rosacea in adults Minocycline 40mg extended-release capsule: • Once-daily (QD) oral dosing; 16-week treatment duration • Each capsule contains a proprietar
Slide 12: EMROSI Demonstrated Superior Efficacy Over Oracea and Placebo
PHASE 3 EMROSI DEMONSTRATED SUPERIOR EFFICACY OVER ORACEA® ® (Co-Primary Endpoints) AND PLACEBO IN TWO PHASE 3 CLINICAL TRIALS IGA Treatment Success: Emrosi was statistically superior to Oracea and placebo in IGA Treatment Success - Week 161 Inflammatory Lesion Reduction - Week 161 the % of patients
Slide 13: EMROSI Successful on All Secondary Endpoints
EMROSI WAS SUCCESSFUL ON ALL SECONDARY ENDPOINTS ® PHASE 3 INCLUDING PERCENT CHANGE IN LESION COUNT (Secondary Endpoints) AND ERYTHEMA REDUCTION Inflammatory Lesion Percent Reduction: Inflammatory Lesion % Reduction - Week 161 Erythema Success - Week 161* (Pooled Data) (Pooled Data) Emrosi was stati
Slide 14: EMROSI Onset of Efficacy as Early as Week 2 (IGA)
EMROSI DEMONSTRATED ONSET OF EFFICACY AS EARLY ® PHASE 3 AS WEEK 2 COMPARED TO PLACEBO, AND WAS SUPERIOR (Exploratory Endpoint) AT EACH SUBSEQUENT STUDY VISIT Pooled IGA Treatment Success – Onset of Action2 Pooled IGA Treatment Success - Week 16 2 *All statistical tests were two-sided, with α=0.05 a
Slide 15: EMROSI Onset of Efficacy as Early as Week 2 (Lesion Count)
EMROSI DEMONSTRATED ONSET OF EFFICACY AS EARLY ® PHASE 3 AS WEEK 2 COMPARED TO PLACEBO, AND WAS SUPERIOR (Exploratory Endpoint) AT EACH SUBSEQUENT STUDY VISIT Pooled Inflammatory Lesion Count Reduction – Onset of Action2 *All statistical tests were two-sided, with α=0.05 as level of significance Poo
Slide 16: Phase 3 Patient Results at Baseline & 16 Weeks
PHASE 3 PATIENT RESULTS AT BASELINE & 16 WEEKS (Efficacy) POST TREATMENT Actual patient images from Emrosi Phase 3 Clinical Trials. Photos used with permission. Results of individual patients may not be typical, as individual results may vary. 16 | © 2026 Journey Medical Corporation. All rights rese
Slide 17: Phase 3 Patient Results at Baseline & 16 Weeks
PHASE 3 PATIENT RESULTS AT BASELINE & 16 WEEKS (Efficacy) POST TREATMENT Actual patient images from Emrosi Phase 3 Clinical Trials. Photos used with permission. Results of individual patients may not be typical, as individual results may vary. 17 | © 2026 Journey Medical Corporation. All rights rese
Slide 18: EMROSI Demonstrated Similar Safety Profile to Placebo
PHASE 3 EMROSI DEMONSTRATED A SIMILAR SAFETY PROFILE ® (Safety) TO PLACEBO1,2 IN PHASE 3 STUDIES1 Key Treatment-Related Adverse Events (N=638) Emrosi (Minocycline, 40mg) 14% (N=243) Oracea® (Doxycycline, 40mg) 12% (N=237) Placebo 10% (N=158) % of Patients 8% The frequency of key treatment-related ad
Slide 19: EMROSI Superior Efficacy to Oracea, Which Had $252 Million Gross Sales
EMROSI HAS SUPERIOR EFFICACY TO ORACEA® (doxycycline, 40 mg), ® WHICH HAD 2025 GROSS SALES OF $252 MILLION STRATEGIC RATIONALE • Robust clinical data demonstrating superior efficacy over Oracea with a placebo-like safety profile ESTIMATED U.S. ROSACEA PATIENTS (2025) • Efficacy is the primary driver
Slide 20: Sales Force Covers Vast Majority of Oral Rosacea Prescriptions
JOURNEY MEDICAL’S SALES FORCE COVERS THE VAST MAJORITY OF ORAL PRESCRIPTIONS FOR ROSACEA IN DERMATOLOGY1 2025 ORAL ROSACEA TRx 2025 ORAL ROSACEA TRx: In Dermatology (717,104 Total TRx)1 (671,388 Total TRx)1 45,716 671,388 582,741 88,647 6% 94% 87% 13% JMC Direct Sales Coverage Non-Direct Promotion N
Slide 21: EMROSI: Commercial Progress
EMROSI : COMMERCIAL PROGRESS ® Emrosi® has surpassed both Oracea® EMROSI TRx ® (doxycycline 40mg) and its generics as the (By Quarter) 35,882 #1 oral therapy approved for treatment of inflammatory lesions (papules and pustules) 29,968 27,023 of rosacea in adults.1,2 Since launching on April 7, 2025:
Slide 22: EMROSI Key Takeaways
EMROSI KEY TAKEAWAYS ® EMROSI is the best-in-class oral therapy for inflammatory lesions of rosacea ® and is expected to become the new standard of care in rosacea therapy 1. Head-to-head superiority over Oracea® demonstrated in two Phase 3 trials 2. Treatment results in as little as 2 weeks 3. Demo
Slide 23: Business Development Strategy
BUSINESS DEVELOPMENT STRATEGY 3. STRATEGIC INVESTMENT IN LATE-STAGE, PHASE 3 READY ASSETS Recent approval of Emrosi and strong synergies with Fortress Biotech • Emrosi has potential to exceed annual sales of $200M in the U.S., ® plus additional revenue through global out-licensing opportunities 2. G
Slide 24: Corporate Priorities and Objectives in 2026
CORPORATE PRIORITIES AND OBJECTIVES IN 2026 ✓ Continue to generate strong EMROSI TRx and sales growth ® ✓ Continue to increase payer formulary coverage for EMROSI for commercial lives ® ✓ Continue to grow EBITDA and advance toward profitability ✓ Additional peer-reviewed journal articles and confere
Slide 25: NASDAQ: DERM
re) amzeeq (minocycline) topical foam, 4% @URNEY MEDICAL CORPORATION NASDAQ: DERM ACCUTANE hres onium) cic emrosi- (minocycline hydrochloride) ti
Journey Medical — Investor Presentation (October 2026) on 6ix